|
Sartorius Stedim Biotech SA
/ Key word(s): 9 Month figures/Quarter Results
Aubagne, October 19, 2023
Nine-month results 2023 of Sartorius Stedim Biotech
Despite initial signs of recovery towards the end of the third quarter, longer-than-expected soft demand continued to impact the business development of Sartorius Stedim Biotech in the first nine months of 2023. The company recorded a decline in sales revenue and profitability after pandemic-related extraordinary business and additional inventory buildup by customers had triggered strong above average growth in previous years. Based on updated business expectations until year-end, management adapted its guidance for fiscal 2023 on October 12. “The timeline for market normalization has continuously expanded in the first nine months of the year: Customers are reducing inventories at a slower pace than initially assumed, while their investment activity and partially production levels remain muted. Signs of recovery in demand have become visible, and while they are progressing slower than anticipated, we expect the situation to continue to improve in the final quarter. Considering the strong fundamental growth drivers of our markets, we expect profitable growth in 2024 and beyond,” said René Fáber, CEO of Sartorius Stedim Biotech. Business development1 The longer-than-expected normalization of demand continued in all regions, with a recovery trend toward the end of the third quarter. After exceptionally strong growth in prior years due to the pandemic, Sartorius Stedim Biotech recorded consolidated sales revenue of 2,069 million euros in the first nine months of 2023, which corresponds to a decline of 19.0 percent in constant currencies (organic: -20.6 percent; reported: - 20.5 percent). This includes a growth contribution from acquisitions of around 2 percentage points. Excluding the Covid-19-related business, the decline was slightly below 13 percent in constant currencies. Main drivers were ongoing inventory reductions after the end of the pandemic, relatively low production levels at some customers, the largely discontinued business in Russia, and an overall muted investment activity of customers, primarily in China and the USA. The temporarily weaker market environment was also reflected in order intake, which decreased by 31.0 percent in constant currencies (reported: -32.4 percent) to 1,760 million euros in the first nine months. In line with progress made by customers in reducing their inventories, there were signs of a slight recovery in order intake at the end of the third quarter. Underlying EBITDA decreased by 34.9 percent to 594 million euros due to lower volume development and product mix effects. The resulting margin was 28.7 percent (prior-year period: 35.0 percent). Price effects on the procurement and customer sides largely offset each other. Relevant net profit totaled 320 million euros, compared with 607 million euros in the prior-year period. Underlying earnings per share were 3.47 euros (prior-year period: 6.58 euros). The number of employees worldwide stood at 10,849 on September 30, 2023, compared with 11,934 at the end of 2022. Key financial indicators Equity was 2,629 million euros as of September 30, 2023. Following the financing of the Polyplus acquisition, the equity ratio1 stood in line with expectations at 33.0 percent (December 31, 2022: 2,514 million euros and 49.6 percent, respectively), and gross debt was 3,794 million euros (December 31, 2022: 1,136 million euros). Net debt stood at 3,695 million euros, resulting in a ratio of net debt to underlying EBITDA1 of 4.0 (December 31, 2022: 1,029 million euros and 0.9, respectively). Cash flow from investing activities, excluding acquisitions, stood at -377 million euros, compared with -289 million euros in the prior-year period. The ratio of capital expenditures (capex) to sales revenue was 17.9 percent (prior-year period: 11.1 percent). Outlook for fiscal 2023 adapted on October 12 Based on preliminary nine-month results, company management lowered its guidance for the fiscal year 2023 on October 12. Against the backdrop of a slower-than-anticipated industry recovery, Sartorius Stedim Biotech now forecasts a sales revenue decline of around 19 percent; excluding Covid-19-related business a decline of around 14 percent. Acquisitions are expected to contribute around 2 percentage points to the sales revenue development. Due to lower volume expectations and product mix effects, the underlying EBITDA margin is expected to be slightly above 28 percent. The capex ratio is projected at around 18 percent for 2023, with a ratio of net debt to underlying EBITDA at around 4.5. The company confirms its fundamentally positive medium- and long-term market outlook and continues to see itself in a strong competitive position. For 2024, management expects profitable growth and will issue quantitative guidance with the release of the 2023 full-year figures next January. Its mid-term ambition is currently under review, and an update will also be provided in January 2024. All forecast figures are based on constant currencies, as in the past years. Management points out that the dynamics and volatilities in the industry have increased significantly in recent years. In addition, uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries, are playing a greater role. This results in higher uncertainty when forecasting business figures. 1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version. Conference call René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s business results with analysts and investors in a conference call at 12.30 p.m. CEST on October 19, 2023. Please click on the link to register: https://media.choruscall.eu/mediaframe/webcast.html?webcastid=zhpcEBhZ Further information and media content: www.sartorius.com/newsroom Key Performance Indicators for the Nine Months of 2023
1 Prior-year figures have been slightly adjusted due to finalization of purchase price allocation for the acquisition of Albumedix Ltd. 2 cc = constant currency 3 According to customer location 4 Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items 5 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and amortization, as well as based on a normalized financial result and normalized tax rate 6 After non-controlling interest Reconciliation between EBIT and underlying EBITDA
1 Prior-year figures have been slightly adjusted due to finalization of purchase price allocation for the acquisition of Albumedix Ltd. 2 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities and change in valuation of earn-out liability 3 Normalized income tax based on the underlying profit before taxes and amortization
1 Prior-year figures have been slightly adjusted due to finalization of purchase price allocation for the acquisition of Albumedix Ltd. A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications safely, rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies. In 2022, the company generated sales revenue of around 3.5 billion euros. Currently, around 11,000 employees are working for customers around the globe. Contact Petra Kirchhoff Head of Corporate Communications & Investor Relations +49 (0)551 308 1686 petra.kirchhoff@sartorius.com Follow us on X (Twitter) and on LinkedIn. Attachment File: Press Release
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 1752239 |
| End of Announcement - EQS News Service | |
|
|
1752239 19-Oct-2023 CET/CEST
